Janus Henderson Group PLC Trims Holdings in Teleflex Incorporated (TFX)
Janus Henderson Group PLC reduced its position in shares of Teleflex Incorporated (NYSE:TFX) by 9.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 794,581 shares of the medical technology company’s stock after selling 81,554 shares during the quarter. Janus Henderson Group PLC owned about 1.73% of Teleflex worth $213,113,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in Teleflex by 4.9% during the 1st quarter. BlackRock Inc. now owns 4,940,818 shares of the medical technology company’s stock worth $1,259,811,000 after purchasing an additional 231,477 shares during the period. American Century Companies Inc. increased its holdings in Teleflex by 1.0% during the 1st quarter. American Century Companies Inc. now owns 1,489,678 shares of the medical technology company’s stock worth $379,838,000 after purchasing an additional 15,069 shares during the period. Summit Trail Advisors LLC increased its holdings in Teleflex by 23,599.0% during the 1st quarter. Summit Trail Advisors LLC now owns 1,181,159 shares of the medical technology company’s stock worth $1,181,000 after purchasing an additional 1,176,175 shares during the period. USS Investment Management Ltd increased its holdings in Teleflex by 44.9% during the 1st quarter. USS Investment Management Ltd now owns 579,590 shares of the medical technology company’s stock worth $155,310,000 after purchasing an additional 179,600 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Teleflex by 0.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 548,319 shares of the medical technology company’s stock worth $147,064,000 after purchasing an additional 1,783 shares during the period. Institutional investors own 88.80% of the company’s stock.
In other Teleflex news, VP John Deren sold 1,347 shares of Teleflex stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $284.57, for a total transaction of $383,315.79. Following the completion of the sale, the vice president now owns 1,419 shares of the company’s stock, valued at approximately $403,804.83. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Andrew A. Krakauer purchased 1,000 shares of the stock in a transaction on Wednesday, August 8th. The shares were purchased at an average cost of $237.56 per share, with a total value of $237,560.00. Following the transaction, the director now owns 1,002 shares in the company, valued at approximately $238,035.12. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 74,002 shares of company stock valued at $19,558,163. 2.56% of the stock is currently owned by insiders.
Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, August 2nd. The medical technology company reported $2.47 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.41 by $0.06. Teleflex had a return on equity of 17.32% and a net margin of 3.78%. The firm had revenue of $609.87 million during the quarter, compared to analysts’ expectations of $615.97 million. During the same quarter last year, the firm earned $2.04 EPS. The business’s quarterly revenue was up 15.4% on a year-over-year basis. equities research analysts expect that Teleflex Incorporated will post 9.82 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 14th. Shareholders of record on Wednesday, August 15th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Tuesday, August 14th. This represents a $1.36 dividend on an annualized basis and a yield of 0.55%. Teleflex’s dividend payout ratio is currently 16.19%.
A number of brokerages have recently issued reports on TFX. Leerink Swann lifted their price target on Teleflex from $309.00 to $317.00 and gave the company an “outperform” rating in a report on Tuesday, June 5th. Needham & Company LLC lifted their price target on Teleflex from $293.00 to $298.00 and gave the company a “buy” rating in a report on Tuesday, May 15th. Deutsche Bank set a $255.00 price target on Teleflex and gave the company a “hold” rating in a report on Friday, May 4th. ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a report on Friday, August 3rd. Finally, TheStreet downgraded Teleflex from a “b” rating to a “c+” rating in a report on Friday, August 3rd. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $281.10.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
See Also: Diversification Important in Investing
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.